Tested heart-risk drug for people with recent heart-attack genetics
Part of Heart & circulation clinical trials.
This trial studies whether dalcetrapib can lower future heart and blood-vessel risk in people who recently had an ACS (acute coronary syndrome, often a heart attack or unstable chest pain) and have a specific genetic marker. It may help people like you by targeting a risk pathway related to that genetic background.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were hospitalized for ACS within the last 3 months and are now medically stable (no heart pain at rest and only minimal symptoms for at least 1 week)
- You are age 45 or older
- Your genetic test shows the required AA genotype from a study-approved testing site
- You have already been started on recommended LDL (“bad cholesterol”) treatment, including medicines and/or diet, before joining
- You can be randomized within 3 months of your index ACS event
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking dabigatran (a blood thinner) combined with ticagrelor (a blood clot preventer) is safe and effective for patients with irregular heart rhythm (atrial fibrillation) who recently had a heart attack and received a stent. The goal is to prevent future blood clots while minimizing bleeding risks.
This study tests whether a personalized score (OPT-CAD) can help decide the best time to stop or reduce blood-thinning medication in people who have had a heart attack and a stent placed. It aims to balance preventing future heart issues while lowering the risk of bleeding.
This trial tests a new medication, AZD0780, to see if it helps prevent major cardiovascular events like heart attacks or strokes in people who already have heart or blood vessel disease, or are at high risk for a first event. It might be a good fit if your cholesterol isn't well-controlled despite current treatments.
This trial tests whether two medicines, a statin and colchicine, can slow or stop early heart artery plaque from growing in people who have mild plaque but no heart disease symptoms yet. It uses special CT scans to measure plaque over 2 years.
This trial tests whether choosing a blood thinner based on your DNA can prevent more heart problems. If you've had a complex heart procedure, you may be able to get a medication that works best for your body.
This trial tests a shorter course of dual antiplatelet therapy (aspirin plus ticagrelor) after stent placement, switching early to just ticagrelor alone. It aims to see if this approach can safely reduce bleeding risks while still protecting against heart problems in people with stable coronary artery disease.
Hear when a new Acute Coronary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.